SIGA Technologies saw no growth in patent filings and highest growth of 0.32% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.32%. GlobalData’s DataBook provides a comprehensive analysis of SIGA Technologies’s patent filings and grants. Buy the databook here.
SIGA Technologies has been focused on protecting inventions in Belgium(BE) with one publication in Q2 2024
The Belgium(BE) Patent Office dominates the patent grants with nearly 100% of grants. The United States(US), and Belgium(BE) patent Office are among the top ten patent offices where SIGA Technologies is filings its patents. Among the top granted patent authorities, SIGA Technologies has 100% of its grants in Belgium(BE).
Gilead Sciences could be the strongest competitor for SIGA Technologies
Orthopoxvirus infections related patents lead SIGA Technologies portfolio followed by dermatitis (eczema), and viral infections
SIGA Technologies has highest number of patents in orthopoxvirus infections followed by dermatitis (eczema), viral infections, poxviridae infections, and monkeypox. For orthopoxvirus infections, nearly 33% of patents were filed and 20% of patents were granted in Q2 2024.
For comprehensive analysis of SIGA Technologies's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.